Clinical Trial Update: Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of gemcitabine with or without imatinib mesylate in previously treated metastatic breast cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-11-29